BRCA1 and ovarian cancer: Preclinical testing in vivo (patient-derived xenograft, PDX) and in vitro (EOC cells—SKOV3, OVCAR3, OVCAR4, UWB1.289+BRCA1 wild type (BRCA1 WT) and UWB1.289 BRCA1 null (BRCA1 Null)) models showed that INCB054329 sensitized the cells to PARPi reducing cell growth, increasing DNA damage and apoptosis in the HR-proficient ovarian cancer cells [70].